Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development
Reference number: GID-TA10858
Expected publication date: TBC
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma after a BTK inhibitor.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.